Company intelligence / Profile preview
Cordex Pharma
La Jolla, California, United Statescordexpharma.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Cordex Pharma developed cardiovascular drugs based on ATP and NO pharmacology. Its lead candidate, ATPace, reached Phase 3 trials for paroxysmal supraventricular tachycardia around 2009. Another candidate, CDP-1050, was in Phase 2 development for heart failure at that time. The company also had a preclinical program targeting chronic obstructive pulmonary disease via a novel pathway[5]. No recent clinical results are available.
- Therapeutic areas
- PulmonologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Cato BioVentures/Cato Research – strategic master services agreement focused on regulatory and clinical oversight for pivotal trials
Beyond the preview
Go deeper on Cordex Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cordex Pharma.